12.27.23
Innovent Biologics, a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and SanegeneBio have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908.
SGB-3908 is an IND-enabling stage siRNA drug developed based on SanegeneBio's LEAD (Ligand and Enhancer Assisted Delivery) platform. Both parties will be jointly responsible for the development of SGB-3908 to certain stage. Innovent has an exclusive option to obtain the exclusive development, manufacturing, and commercialization license of SGB-3908 in different areas worldwide. After Innovent exercises its option, SanegeneBio will be eligible to receive subsequent milestone payments, as well as royalties on sales.
The alliance combines SanegeneBio’s RNA technology and Innovent's clinical development experience and commercialization capability to help accelerate development and commercial success.